@kinglongthu

cell and gene therapy business development at Thermo Fisher Scientific , Vandy and Tsinghua alum, views mine, email: jinlong.ding AT https://xitter.cf/t.co/YVirmsX0yp

linkedin.com/in/jinlongding
Joined November 2009
  • Tweets352
  • Following1.1K
  • Followers210
15Media
Thermo Fisher Nears Deal for Solventum Filtration Unit on.wsj.com/3XEQhTF
4
7
6,201
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial hubs.li/Q032dPqh0
Kaplan–Meier curves of duration of response by disease histology (A) and duration of response by LBCL subset (B; previous CART category includes patients from both de novo DLBCL and other LBCL categories). Copyright: 2024 Elsevier Ltd. All rights are reserved.

ALT Kaplan–Meier curves of duration of response by disease histology (A) and duration of response by LBCL subset (B; previous CART category includes patients from both de novo DLBCL and other LBCL categories). Copyright: 2024 Elsevier Ltd. All rights are reserved.

1
6
26
8,361
Jinlong retweeted
nature
@Nature23 Oct 2024
Nature research paper: Machine-guided design of cell-type-targeting cis-regulatory elements go.nature.com/3A0nksF
5
47
1
167
27,860
🚨Fantastic pair of papers in @Nature today from @EvanWeberPhD, @MackallLab and the Darcy lab @PeterMacCC on enforcing stem-like molecular programs in therapeutic T cells through overexpression of #FOXO1! 👇 nature.com/articles/s41586-0…. @ChildrensPhila @StanfordCancer @parkerici

FOXO1 is a master regulator of memory programming in CAR T cells

Nature - The transcription factor FOXO1 has a key role in human T cell memory, and manipulating FOXO1 expression could provide a way to enhance CAR T cell therapies by increasing CAR T cell...

nature.com
3
21
131
10,072
Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity dlvr.it/T5745P
3
5
2,089
Online now! Genetic retargeting of E3 ligases to enhance CAR T cell therapy by @isabel_c_lane, @janlabmgh, and colleagues at @harvardmed @MassGeneralNews @broadinstitute and others dlvr.it/Sz4qzQ #chembiol #CART #E3Ligase

Genetic retargeting of E3 ligases to enhance CAR T cell therapy

Many genes that limit CAR T cell therapy are difficult to target with existing modalities. Lane et al. developed bifunctional degrader proteins to bridge an E3 ligase and one or more endogenous...

cell.com
3
12
4,521
Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration go.nature.com/3QNaKT9
4
17
75
40,912
Building smart CAR T cell therapies: The path to overcome current challenges dlvr.it/SxG65Y
12
32
6,917
Now online! Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity dlvr.it/SrkVWF

Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity

Vaccine boosting modifies CAR T cell metabolism and promotes crosstalk between CAR T cells and endogenous immunity to elicit and sustain antigen spreading, thereby effectively treating tumors with...

cell.com
32
1
88
26,754
Jinlong retweeted
nature
@Nature23 Jun 2023
Nature research paper: Physiology and diseases of tissue-resident macrophages go.nature.com/3NmIN1m
27
1
88
30,501
At #ADA2023, Fractyl Health’s landmark oral presentation highlighted the promising implications of the Rejuva® platform in potentially reshaping the treatment landscape for #T2D and #obesity with a one-time, durable, tissue-specific #genetherapy. fractyl.com/fractyl-health-d…
1
5
6
632
Congratulations to @JessieRoseDavis, @samagyabanskota, Jonathan M. Levy, @Gregory_Newby, @XiaoWan10346554, Andrew Anzalone, @Andrew_TNelson, @PeterJ_Chen, @andrew_hennes, Meirui An, @heejin_roh, Peyton B. Randolph, and @kiranmusunuru! Link to PDF: drive.google.com/file/d/11uk… 4/4

Efficient prime editing in mouse brain, liver and heart with dual AAVs.pdf

drive.google.com
9
46
8,541
Efficient prime editing in mouse brain, liver and heart with dual AAVs go.nature.com/3HHdBrA
2
21
57
28,494
Here is an updated version of my #AAV #formulation landscape poster. Feel free to use. #genetherapy #ATMP linkedin.com/posts/activity-…

#genetherapy #atmp #gmp #manufacturing #formulation #aav #genetherapy | Philipp Beck

Updated 🆙 AAV #genetherapy formulation landscape 💊  With many tweaks & additions thanks to my eagle-eyed colleagues Andrew Steinsapir Sebastian Sedlmeier & Joanne Broadhead I totally missed the...

linkedin.com
1
2
148
Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies dlvr.it/SlZMSs
1
1
49
Excited to share our new CLASH platform published at Nature Biotechnology! mass knock-in engineering in human T cells and beyond nature.com/articles/s41587-0… @YaleMed @YaleGenetics @YaleCancer @YaleWestCampus @NatureBiotech

Massively parallel knock-in engineering of human T cells

Nature Biotechnology - Unbiased selection of CAR-T cells is achieved by massively parallel knock-in engineering.

nature.com
6
96
6
403
74,442
Massively parallel knock-in engineering of human T cells go.nature.com/3WPqyEM
4
39
3
158
38,552
Results of the first-in-human trial of an enhanced T cell therapy that targets multiple solid tumors bearing the antigen MAGE-A4, showed noteworthy outcomes in several cancers, particularly synovial sarcoma. Read more: ow.ly/V96K50MmGKw
1
5
16
2,519
Earlier today we announced a strategic update, including portfolio reprioritization and research and development realignment. Learn more: bit.ly/3jWbQOh #geneediting #biotechnology
1
2
1,120
Jinlong retweeted
U.S. FDA
@FDA16 Dec 2022
Today, we approved the first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer. fda.gov/news-events/press-an…
7
12
3
34
14,477
Load more